Congruence Therapeutics (also known as Congruence Thérapeutique) is a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. It uses the interface of structural bioinformatics, computational chemistry, and machine learning to deploy an in-silico platform that enables the design of pharmacological stabilizers.